| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1930 | 2020 |
| An intra-tumoral niche maintains and differentiates stem-like CD8 T cells CS Jansen, N Prokhnevska, VA Master, MG Sanda, JW Carlisle, MA Bilen, ... Nature 576 (7787), 465-470, 2019 | 688 | 2019 |
| Frailty and cancer: implications for oncology surgery, medical oncology, and radiation oncology CG Ethun, MA Bilen, AB Jani, SK Maithel, K Ogan, VA Master CA: a cancer journal for clinicians 67 (5), 362-377, 2017 | 556 | 2017 |
| Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium P Grivas, AR Khaki, TM Wise-Draper, B French, C Hennessy, CY Hsu, ... Annals of oncology 32 (6), 787-800, 2021 | 315 | 2021 |
| Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19 MA Thompson, JP Henderson, PK Shah, SM Rubinstein, MJ Joyner, ... JAMA oncology 7 (8), 1167-1175, 2021 | 187 | 2021 |
| Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer CJ Hoimes, TW Flaig, MI Milowsky, TW Friedlander, MA Bilen, S Gupta, ... Journal of clinical oncology 41 (1), 22-31, 2023 | 180 | 2023 |
| CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor N Prokhnevska, MA Cardenas, RM Valanparambil, E Sobierajska, ... Immunity 56 (1), 107-124. e5, 2023 | 172 | 2023 |
| Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience T Fujii, RR Colen, MA Bilen, KR Hess, J Hajjar, ME Suarez-Almazor, ... Investigational new drugs 36, 638-646, 2018 | 171 | 2018 |
| Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study NM Chanzá, W Xie, MA Bilen, H Dzimitrowicz, J Burkart, DM Geynisman, ... The lancet oncology 20 (4), 581-590, 2019 | 160 | 2019 |
| Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts CF Huang, C Lira, K Chu, MA Bilen, YC Lee, X Ye, SM Kim, A Ortiz, ... Cancer research 70 (11), 4580-4589, 2010 | 152 | 2010 |
| Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study CH Lee, AY Shah, D Rasco, A Rao, MH Taylor, C Di Simone, JJ Hsieh, ... The lancet oncology 22 (7), 946-958, 2021 | 149 | 2021 |
| BMP4 promotes prostate tumor growth in bone through osteogenesis YC Lee, CJ Cheng, MA Bilen, JF Lu, RL Satcher, LY Yu-Lee, GE Gallick, ... Cancer research 71 (15), 5194-5203, 2011 | 149 | 2011 |
| 18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label … AB Jani, E Schreibmann, S Goyal, R Halkar, B Hershatter, PJ Rossi, ... The Lancet 397 (10288), 1895-1904, 2021 | 146 | 2021 |
| The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced‐stage cancer treated with immunotherapy MA Bilen, DJ Martini, Y Liu, C Lewis, HH Collins, JM Shabto, M Akce, ... Cancer 125 (1), 127-134, 2019 | 143 | 2019 |
| Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. JE Rosenberg, TW Flaig, TW Friedlander, MI Milowsky, S Srinivas, ... Journal of Clinical Oncology 38 (6_suppl), 441-441, 2020 | 123 | 2020 |
| Radiomics to predict immunotherapy-induced pneumonitis: proof of concept RR Colen, T Fujii, MA Bilen, A Kotrotsou, S Abrol, KR Hess, J Hajjar, ... Investigational new drugs 36, 601-607, 2018 | 113 | 2018 |
| Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody MA Bilen, SK Subudhi, J Gao, NM Tannir, SM Tu, P Sharma Journal for immunotherapy of cancer 4, 1-5, 2016 | 110 | 2016 |
| Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis, H Collins, M Akce, ... BMC cancer 19, 1-8, 2019 | 109 | 2019 |
| Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA N Agarwal, SK Pal, AW Hahn, RH Nussenzveig, GR Pond, SV Gupta, ... Cancer 124 (10), 2115-2124, 2018 | 100 | 2018 |
| Impact of performance status on treatment outcomes: A real‐world study of advanced urothelial cancer treated with immune checkpoint inhibitors AR Khaki, A Li, LN Diamantopoulos, MA Bilen, V Santos, J Esther, ... Cancer 126 (6), 1208-1216, 2020 | 86 | 2020 |
